Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T23:16:17.340Z Has data issue: false hasContentIssue false

Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE)

Published online by Cambridge University Press:  24 November 2021

Katie J. Suda*
Affiliation:
Department of Veterans’ Affairs, Center for Health Equity Research and Promotion, Veterans’ Health Administration (VA) Pittsburgh Healthcare System, Pittsburgh, PennsylvaniaDivision of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Alfredo Traversa
Affiliation:
Internal Medicine, Rush University Medical Center, Chicago, Illinois
Ursula Patel
Affiliation:
Department of Veterans’ Affairs, Edward Hines Jr VA Hospital, Hines, Illinois
Linda Poggensee
Affiliation:
Department of Veterans’ Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, Illinois
Margaret A. Fitzpatrick
Affiliation:
Department of Veterans’ Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, IllinoisDivision of Infectious Diseases, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois
Geneva M. Wilson
Affiliation:
Department of Veterans’ Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, Illinois
Charlesnika T. Evans
Affiliation:
Department of Veterans’ Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, IllinoisCenter for Health Services and Outcomes Research, Department of Preventive Medicine Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
*
Author for correspondence: Dr Katie J. Suda, E-mail: ksuda@pitt.edu
Rights & Permissions [Opens in a new window]

Abstract

We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Patient Demographic and Medical Characteristics of carbapenem-resistant Enterobacterales (CRE) Cultures Overall and Stratified by Bloodstream Infection (BSI) and Non-BSI

Figure 1

Fig. 1.Trends in antibiotics prescribed to veterans with non-BSI cultures positive for carbapenem-resistant Enterobacterales (CRE). P values for trend: aminoglycosides <.0001; carbapenems 0.7985; polymyxins <.0001; fluoroquinolones <.0001; extended spectrum cephalosporins <.0001; penicillins 0.4559; and ceftazidime–avibactam. Ceftazidime–avibactam was approved by the US Food and Drug Administration February 2015 and was available for distribution April 2015. Ceftazidime–avibactam was added to the national VA formulary in December 2015 restricted to infectious disease specialists or facility-authorized provider (when infectious disease specialists are not available at the individual facility). Extended-spectrum cephalosporins included third- and fourth-generation cephalosporins; only ceftazidime and cefepime were prescribed. Cefiderocol was not FDA approved during the study period.

Figure 2

Fig. 2.Trends in antibiotics prescribed to veterans with BSI cultures positive for carbapenem-resistant Enterobacterales (CRE). P value for trends: aminoglycosides 0.0026; carbapenems 0.4741; polymyxins .0019; fluoroquinolones .6411; extended spectrum cephalosporins <.0001; penicillins .7110; and ceftazidime–avibactam.2 Ceftazidime–avibactam was approved by the US Food and Drug Administration February 2015 and was available for distribution April 2015. Ceftazidime–avibactam was added to the national VA formulary in December 2015 restricted to infectious disease specialists or facility-authorized provider (when infectious disease specialists are not available at the individual facility).3 Extended-spectrum cephalosporins included third- and fourth-generation cephalosporins; only ceftazidime and cefepime were prescribed. Cefiderocol was not FDA approved during the study period.

Supplementary material: Image

Suda et al. supplementary material

Figure S1

Download Suda et al. supplementary material(Image)
Image 28.3 KB